Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 30, Number 2—February 2024
CME ACTIVITY - Synopsis

Multicenter Retrospective Study of Invasive Fusariosis in Intensive Care Units, France

Jordane Demonchy, Lucie Biard, Raphaël Clere-Jehl, Florent Wallet, Djamel Mokart, Anne-Sophie Moreau, Laurent Argaud, Camille Verlhac, Frédéric Pène, Alexandre Lautrette, Naïke Bige, Audrey de Jong, Emmanuel Canet, Jean-Pierre Quenot, Nahéma Issa, Yoann Zerbib, Inès Bouard, Muriel Picard, and Lara ZafraniComments to Author 
Author affiliations: Centre Hospitalier Universitaire de Lille, Lille, France (J. Demonchy, A.-S. Moreau); Institut national de la santé et de la recherche médicale (INSERM), University of Paris Cité, Paris, France (J. Demonchy, L. Zafrani); Hôpital Saint-Louis, Paris (L. Biard, I. Bouard, L. Zafrani); Centre Hospitalier Universitaire de Strasbourg, Strasbourg, France (R. Clere-Jehl); Centre Hospitalier Universitaire de Lyon, Lyon, France (F. Wallet, L. Argaud); Institut Paoli-Calmettes, Marseille, France (D. Mokart); Centre Hospitalier Universitaire de Clermont-Ferrand, Clermont-Ferrand, France (C. Verlhac, A. Lautrette); Hôpital Cochin, Paris (F. Pène); Hôpital Saint-Antoine, Paris (N. Bige); Montpellier University, INSERM, and St-Eloi Hospital, Montpellier, France (A. de Jong); Centre Hospitalier Universitaire de Nantes, Nantes, France (E. Canet); Centre Hospitalier Universitaire de Dijon Bourgogne, Dijon, France (J.-P. Quenot); Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France (N. Issa); Centre Hospitalier Universitaire de Amiens-Picardie, Amiens, France (Y. Zerbib); Centre Hospitalier Universitaire de Toulouse, Toulouse, France (M. Picard)

Main Article

Figure 1

Flowchart for patient inclusion in a multicenter retrospective study of invasive fusariosis in ICUs, France. *Colonization by Fusarium defined as patient not meeting the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group or National Institute of Allergy and Infectious Diseases Mycoses Study Group criteria for proven or probable invasive fungal diseases (7). ICU, intensive care unit.

Figure 1. Flowchart for patient inclusion in a multicenter retrospective study of invasive fusariosis in ICUs, France. *Colonization by Fusarium defined as patient not meeting the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group or National Institute of Allergy and Infectious Diseases Mycoses Study Group criteria for proven or probable invasive fungal diseases (7). ICU, intensive care unit.

Main Article

References
  1. Pagano  L, Caira  M, Candoni  A, Offidani  M, Fianchi  L, Martino  B, et al. The epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM-2004 study. Haematologica. 2006;91:1068–75.PubMedGoogle Scholar
  2. Borjian Boroujeni  Z, Shamsaei  S, Yarahmadi  M, Getso  MI, Salimi Khorashad  A, Haghighi  L, et al. Distribution of invasive fungal infections: Molecular epidemiology, etiology, clinical conditions, diagnosis and risk factors: A 3-year experience with 490 patients under intensive care. Microb Pathog. 2021;152:104616. DOIPubMedGoogle Scholar
  3. Nucci  M, Barreiros  G, Akiti  T, Anaissie  E, Nouér  SA. Invasive fusariosis in patients with hematologic diseases. J Fungi (Basel). 2021;7:815. DOIPubMedGoogle Scholar
  4. Dignani  MC, Anaissie  E. Human fusariosis. Clin Microbiol Infect. 2004;10(Suppl 1):67–75. DOIPubMedGoogle Scholar
  5. Nucci  M, Anaissie  E. Fusarium infections in immunocompromised patients. Clin Microbiol Rev. 2007;20:695–704. DOIPubMedGoogle Scholar
  6. Tortorano  AM, Richardson  M, Roilides  E, van Diepeningen  A, Caira  M, Munoz  P, et al.; European Society of Clinical Microbiology and Infectious Diseases Fungal Infection Study Group; European Confederation of Medical Mycology. ESCMID and ECMM joint guidelines on diagnosis and management of hyalohyphomycosis: Fusarium spp., Scedosporium spp. and others. Clin Microbiol Infect. 2014;20(Suppl 3):27–46. DOIPubMedGoogle Scholar
  7. De Pauw  B, Walsh  TJ, Donnelly  JP, Stevens  DA, Edwards  JE, Calandra  T, et al.; European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group; National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis. 2008;46:1813–21. DOIPubMedGoogle Scholar
  8. Nucci  M, Marr  KA, Vehreschild  MJGT, de Souza  CA, Velasco  E, Cappellano  P, et al. Improvement in the outcome of invasive fusariosis in the last decade. Clin Microbiol Infect. 2014;20:580–5. DOIPubMedGoogle Scholar
  9. Horn  DL, Freifeld  AG, Schuster  MG, Azie  NE, Franks  B, Kauffman  CA. Treatment and outcomes of invasive fusariosis: review of 65 cases from the PATH Alliance(®) registry. Mycoses. 2014;57:652–8. DOIPubMedGoogle Scholar
  10. Lortholary  O, Obenga  G, Biswas  P, Caillot  D, Chachaty  E, Bienvenu  AL, et al.; French Mycoses Study Group. International retrospective analysis of 73 cases of invasive fusariosis treated with voriconazole. Antimicrob Agents Chemother. 2010;54:4446–50. DOIPubMedGoogle Scholar
  11. Campo  M, Lewis  RE, Kontoyiannis  DP. Invasive fusariosis in patients with hematologic malignancies at a cancer center: 1998-2009. J Infect. 2010;60:331–7. DOIPubMedGoogle Scholar
  12. Batista  BG, Chaves  MA, Reginatto  P, Saraiva  OJ, Fuentefria  AM. Human fusariosis: An emerging infection that is difficult to treat. Rev Soc Bras Med Trop. 2020;53:e20200013. DOIPubMedGoogle Scholar
  13. Chan  TSY, Au-Yeung  R, Chim  CS, Wong  SCY, Kwong  YL. Disseminated fusarium infection after ibrutinib therapy in chronic lymphocytic leukaemia. Ann Hematol. 2017;96:871–2. DOIPubMedGoogle Scholar
  14. Delia  M, Monno  R, Giannelli  G, Ianora  AAS, Dalfino  L, Pastore  D, et al. Fusariosis in a patient with acute myeloid leukemia: a case report and review of the literature. Mycopathologia. 2016;181:457–63. DOIPubMedGoogle Scholar
  15. Fei  H, Liu  X, Sun  L, Shi  X, Wang  W, Zhao  H, et al. Disseminated fusarium infection after allogeneic hematopoietic stem cell transplantation after CART: A case report. Medicine (Baltimore). 2022;101:e31594. DOIPubMedGoogle Scholar
  16. Nucci  M, Anaissie  EJ, Queiroz-Telles  F, Martins  CA, Trabasso  P, Solza  C, et al. Outcome predictors of 84 patients with hematologic malignancies and Fusarium infection. Cancer. 2003;98:315–9. DOIPubMedGoogle Scholar
  17. Pérez-Nadales  E, Alastruey-Izquierdo  A, Linares-Sicilia  MJ, Soto-Debrán  JC, Abdala  E, García-Rodríguez  J, et al.; Spanish Fusariosis Study Group. Invasive fusariosis in nonneutropenic patients, Spain, 2000–2015. Emerg Infect Dis. 2021;27:26–35. DOIPubMedGoogle Scholar
  18. Thomas  B, Audonneau  NC, Machouart  M, Debourgogne  A. Fusarium infections: Epidemiological aspects over 10 years in a university hospital in France. J Infect Public Health. 2020;13:1089–93. DOIPubMedGoogle Scholar
  19. Girmenia  C, Pagano  L, Corvatta  L, Mele  L, del Favero  A, Martino  P. The epidemiology of fusariosis in patients with haematological diseases. Gimema Infection Programme. Br J Haematol. 2000;111:272–6. DOIPubMedGoogle Scholar
  20. Le Gall  JR, Lemeshow  S, Saulnier  F. A new Simplified Acute Physiology Score (SAPS II) based on a European/North American multicenter study. JAMA. 1993;270:2957–63. DOIPubMedGoogle Scholar
  21. Vincent  JL, de Mendonça  A, Cantraine  F, Moreno  R, Takala  J, Suter  PM, et al. Use of the SOFA score to assess the incidence of organ dysfunction/failure in intensive care units: results of a multicenter, prospective study. Working group on “sepsis-related problems” of the European Society of Intensive Care Medicine. Crit Care Med. 1998;26:1793–800. DOIPubMedGoogle Scholar
  22. Gangneux  JP, Dannaoui  E, Fekkar  A, Luyt  CE, Botterel  F, De Prost  N, et al. Fungal infections in mechanically ventilated patients with COVID-19 during the first wave: the French multicentre MYCOVID study. Lancet Respir Med. 2022;10:180–90. DOIPubMedGoogle Scholar
  23. Boutati  EI, Anaissie  EJ. Fusarium, a significant emerging pathogen in patients with hematologic malignancy: ten years’ experience at a cancer center and implications for management. Blood. 1997;90:999–1008. DOIPubMedGoogle Scholar
  24. Hotchkiss  RS, Monneret  G, Payen  D. Immunosuppression in sepsis: a novel understanding of the disorder and a new therapeutic approach. Lancet Infect Dis. 2013;13:260–8. DOIPubMedGoogle Scholar
  25. Nucci  F, Nouér  SA, Capone  D, Nucci  M. Invasive mould disease in haematologic patients: comparison between fusariosis and aspergillosis. Clin Microbiol Infect. 2018;24:1105.e1–4. DOIPubMedGoogle Scholar
  26. Marom  EM, Holmes  AM, Bruzzi  JF, Truong  MT, O’Sullivan  PJ, Kontoyiannis  DP. Imaging of pulmonary fusariosis in patients with hematologic malignancies. AJR Am J Roentgenol. 2008;190:1605–9. DOIPubMedGoogle Scholar
  27. Sassi  C, Stanzani  M, Lewis  RE, Vianelli  N, Tarsi  A, Poerio  A, et al. Radiologic findings of Fusarium pneumonia in neutropenic patients. Mycoses. 2017;60:73–8. DOIPubMedGoogle Scholar
  28. Naesens  M, Kuypers  DRJ, Sarwal  M. Calcineurin inhibitor nephrotoxicity. Clin J Am Soc Nephrol. 2009;4:481–508. DOIPubMedGoogle Scholar
  29. Al-Hatmi  AMS, Bonifaz  A, Ranque  S, Sybren de Hoog  G, Verweij  PE, Meis  JF. Current antifungal treatment of fusariosis. Int J Antimicrob Agents. 2018;51:326–32. DOIPubMedGoogle Scholar
  30. Kontoyiannis  DP, Bodey  GP, Hanna  H, Hachem  R, Boktour  M, Girgaway  E, et al. Outcome determinants of fusariosis in a tertiary care cancer center: the impact of neutrophil recovery. Leuk Lymphoma. 2004;45:139–41. DOIPubMedGoogle Scholar

Main Article

Page created: November 30, 2023
Page updated: January 22, 2024
Page reviewed: January 22, 2024
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external